These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29286132)

  • 41. Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells.
    Naimi A; Safaei S; Entezari A; Solali S; Hassanzadeh A
    Anticancer Agents Med Chem; 2020; 20(5):571-579. PubMed ID: 32000648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
    Lei J; Xiao JH; Zhang SH; Liu ZQ; Huang K; Luo ZP; Xiao XL; Hong ZD
    Mol Med Rep; 2017 Oct; 16(4):4273-4278. PubMed ID: 28765891
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma.
    Liang J; Zhang Y; Jiang G; Liu Z; Xiang W; Chen X; Chen Z; Zhao J
    Oncol Res; 2013; 21(2):83-91. PubMed ID: 24406044
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypoxia-induced NIPP1 activation enhances metastatic potential and predicts poor prognosis in hepatocellular carcinoma.
    Huang Y; Tao Y; Hu K; Lin F; Li X; Feng T; Wang ZM
    Tumour Biol; 2016 Nov; 37(11):14903-14914. PubMed ID: 27644248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
    Eichenauer T; Simmendinger L; Fraune C; Mandelkow T; Blessin NC; Kluth M; Hube-Magg C; Möller K; Clauditz T; Weidemann S; Dahlem R; Fisch M; Riechardt S; Simon R; Sauter G; Büscheck F; Rink M
    World J Urol; 2021 Feb; 39(2):481-490. PubMed ID: 32303902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
    Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
    J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
    Sakurai T; Bilim VN; Ugolkov AV; Yuuki K; Tsukigi M; Motoyama T; Tomita Y
    Biochem Biophys Res Commun; 2012 Jun; 422(4):607-14. PubMed ID: 22609199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
    Tian X; Xu J; Fletcher C; Hornick JL; Dorfman DM
    Mod Pathol; 2018 Apr; 31(4):553-561. PubMed ID: 29327713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
    J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EZH2-mediated inhibition of KLF14 expression promotes HSCs activation and liver fibrosis by downregulating PPARγ.
    Du Z; Liu M; Wang Z; Lin Z; Feng Y; Tian D; Xia L
    Cell Prolif; 2021 Jul; 54(7):e13072. PubMed ID: 34031939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
    Wan Z; Jiang H; Li L; Zhu S; Hou J; Yu Y
    Bioorg Med Chem; 2020 Apr; 28(7):115379. PubMed ID: 32098708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
    Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP
    Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
    Lee HW; Choe M
    Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 58. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells.
    Wei Z; Jiang X; Qiao H; Zhai B; Zhang L; Zhang Q; Wu Y; Jiang H; Sun X
    Cell Signal; 2013 Apr; 25(4):931-8. PubMed ID: 23333463
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LINC00997, a novel long noncoding RNA, contributes to metastasis via regulation of S100A11 in kidney renal clear cell carcinoma.
    Chang Y; Li N; Yuan W; Wang G; Wen J
    Int J Biochem Cell Biol; 2019 Nov; 116():105590. PubMed ID: 31442606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. miR‑92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2.
    Liu F; Sang M; Meng L; Gu L; Liu S; Li J; Geng C
    Int J Oncol; 2018 Oct; 53(4):1505-1515. PubMed ID: 30066891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.